Solasia Pharma K.K. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2020; Provides Earnings Guidance for the Fiscal Year Ending December 31, 2020
For the fiscal year ending December 31, 2020, for the period, the company expects revenue to be between JPY 500 million and JPY 2,000 million, operating loss to be between JPY 2,900 million and JPY 2,000 million, Loss attributable to owners of parent to be between JPY 2,900 million and JPY 2,000 million a year ago. Basic loss per share expects to be between JPY 24.91 and JPY 17.18.